Sodium valproate inhibits MDA-MB-231 breast cancer cell migration by upregulating NM23H1 expression
“Sodium valproate inhibits MDA-MB-231 breast cancer cell migration by upregulating NM23H1 expression”, vol. 11, pp. 77-86, 2012.
, Breast cancer is a common cancer in women, with a highly variable course, from inoffensive to lethal. To find a more effective strategy for its treatment, sodium valproate has been tested as an anti-cancer drug; it is the only clinically available histone deacetylase inhibitor. However, data about the effects of sodium valproate on breast cancer are insufficient in both animals and humans; studies have yielded conflicting conclusions. In particular, little is known about the association between expression of the metastasis suppressor Nm23H1 gene and breast cancer.